CT imaging findings of lenvatinib-induced enteritis
| Autor: | Mariko Kurokawa, Tomoya Tanishima, Moto Nakaya, Yoshiaki Ota, Wataru Gonoi, Shohei Inui, Akifumi Hagiwara, Osamu Abe, Ryo Kurokawa, Nana Fujita, Yudai Nakai, Shiori Amemiya, Akira Baba |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Nausea Urology Antineoplastic Agents Gastroenterology Enteritis chemistry.chemical_compound Internal medicine medicine Carcinoma Humans Radiology Nuclear Medicine and imaging Adverse effect Aged Retrospective Studies Aged 80 and over Radiological and Ultrasound Technology business.industry Phenylurea Compounds Liver Neoplasms Middle Aged medicine.disease medicine.anatomical_structure chemistry Hepatocellular carcinoma Quinolines Duodenum Vomiting medicine.symptom Tomography X-Ray Computed Lenvatinib business |
| Zdroj: | Abdominal Radiology. 46:3066-3074 |
| ISSN: | 2366-0058 2366-004X |
| Popis: | To evaluate the relationship between abnormal findings on abdomino-pelvic CT and adverse events in oncologic patients treated with lenvatinib, and their relationship with treatment planning. This single institutional retrospective study included 58 patients with unresectable hepatocellular carcinoma or unresectable thyroid carcinoma (mean age ± standard deviation 69.6 ± 10.0 years; range 39–84 years; 48 men) who underwent CT between October 2016 and July 2020. Two radiologists who were blinded to clinical information including the presence or absence of diarrhea evaluated the imaging findings, including the presence/absence of enteritis in each intestinal segment. Gastrointestinal adverse events (diarrhea, decreased appetite, nausea, and vomiting) and other drug-induced adverse events requiring treatment or follow-up during lenvatinib treatment were also investigated. The frequency of these adverse events was compared between the patients with and without enteritis using Fisher’s exact test or the Mann–Whitney U test. Enteritis was found on CT in the majority (33/58 [56.9%]) of the patients, and most of them (25/33 [75.8%]) showed duodenojejunitis. The frequency of gastrointestinal adverse events (28/33 [84.8%] vs. 13/25 [56.0%], p = 0.009), diarrhea (20/33 [60.6%] vs. 3/25 [12.0%], p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink